Skip to content

In-Silico Identification and Molecular Dynamics Characterization of FDA-Approved Drug Candidates Targeting MAO-B for Parkinson’s Disease Drug Repurposing

Sep 2026 · Journal of Pharmaceutical Innovation · Vol 22 · 0 citations · 47 references

TL;DR

A knowledge-based virtual screening and drug-repurposing workflow was applied to identify FDA-approved small molecules predicted to bind favourably to MAO-B, highlighting apixaban and rimacalib as predicted MAO-B-binding candidates warranting biochemical and pharmacological validation to establish their repurposing potential for PD.

View source

Similar papers

Open access Oct 2026

Drug repurposing for psoriasis: virtual screening, molecular dynamics, and ADMET profiling for the identification of potential DHFR inhibitors

Findings suggest Velpatasvir and Ledipasvir as promising DHFR inhibitors warranting experimental validation, and demonstrate drug repurposing as a cost-effective strategy for discovering novel psoriasis therapies.

Sadaf Naeem, Syeda Zoya Mahmood, Subohi Noorulain et al. · 0 citations
Oct 2026

Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds.

Cyclin-dependent kinase 6 (CDK6) contributes to G1-to-S cell-cycle progression and represents an established therapeutic target in hormone receptor-positive breast cancer. However, adverse effects and acquired resistance associated with current CDK4/6 inhibitors support continued investigation of alternative chemical s...

Syarifuddin Husain, Ruzianisra Mohamed, Khairul Bariyyah Abd. Halim et al. · 0 citations
Open access Sep 2026

Fungal Metabolites as Multi-Target Modulators of Alzheimer’s Disease: An Integrated In Silico Docking and Molecular Dynamics Approach

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options offering only symptomatic relief. Natural fungal metabolites have recently gained attention for their neuroprotective potential. In this study, an extensive library of 18,349 fungal compounds was retrieved from the NPA...

Deepeesh Vijayan, Karthick Siva, Jayathraa Ramachandran et al. · 0 citations
Review Open access Aug 2026

Integrated molecular docking, toxicity prediction, and molecular dynamics simulations studies to identify potential antimalarial candidates targeting enoyl-acyl carrier protein reductase enzyme

A cost-effective computational workflow for prioritizing ENR inhibitors is demonstrated, providing a foundation for the development of novel antimalarial agents and highlighting Cd3 and Cd5 as the most promising candidates for further development.

Abozur Mohamed Mohyeldin Khalil, Carlos Eliel Maya-Ramírez, A. A. Razzak Mahmood et al. · 0 citations
Open access Oct 2026

Structure-guided Discovery of a Computationally Prioritized Candidate for MMP-13 Inhibition with Favorable Drug-likeness

Collagenases, a subgroup of matrix metalloproteinases (MMPs), contribute to pathological angiogenesis by degrading extracellular matrix components, and their dysregulation is closely linked to tumor invasion and metastasis. This study aimed to identify potential collagenase inhibitors through an integrated computationa...

Doono Mariya, Deepthy Varghese, Titto Varughese et al. · 0 citations
Open access Sep 2026

Integrating Molecular Docking, Dynamics, and AI-Based ADMET Prediction to Decipher the Toxicity Profile of Isometamidium Chloride Against Animal Trypanosomiasis

Isometamidium chloride (ISM) is a widely used trypanocidal drug for treating animal trypanosomiasis, despite concerns about toxicity, and emerging drug resistance. A comprehensive in silico evaluation integrating molecular interaction analysis, pharmacokinetic profiling, toxicity prediction, and molecular dynamics simu...

S. Batheja, S. Choudhary, Swati Rani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.